Skip to content
Screener

Glaukos GKOS Glaucoma — Revenue

Other product segments

Corneal Health
$30.43M+47.8%

Similar metrics at other companies

Sight Sciences, Inc. logo
SGHTSurgical Glaucoma — Revenue
$20.71M+7.7%
HRO
HROWOther Revenues — Revenue
$73K-15.1%
Oracle logo
ORCLCloud Revenues — Revenue
$9.91B+47.1%
Oracle logo
ORCLSoftware Revenues — Revenue
$6.82B-2.1%
Blue Owl Capital logo
OWLPerformance revenues — Revenue
$6.07M-3.9%
EAT
EATFranchise revenues — Revenue
$14.7M+21.5%

Other financials

Income statement

See full
Revenue$185.6M+49.5%
Gross profit$151.6M+55.9%
Operating income-$17.3M+23.9%
Net income-$18.4M+6.5%
EPS (diluted)-$0.31+8.8%

Balance sheet

See full
Cash & equivalents$114.5M+13.6%
Total debt$105.9M-1.4%
Total equity$682.5M-10.8%
Total assets$920.5M-6.7%

Cash flow

See full
Operating cash flow$14.8M—
CapEx$2.7M+132%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$10.08B+98.7%
Enterprise value$10.07B+98.2%
P/S16.5×+4.7×

Profitability

See full
Gross margin61%-15.4pp
Operating margin-31.6%+22.2pp
Net margin-30.7%+23.3pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26%-11,301pp
Debt / equity0.2×0.0×
Current ratio5×-0.5×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Glaukos’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324201
Line itemThree Months Ended / June 30, / United States / 2026Three Months Ended / June 30, / United States / 2025Three Months Ended / June 30, / International / 2026Three Months Ended / June 30, / International / 2025Three Months Ended / June 30, / Total / 2026Three Months Ended / June 30, / Total / 2025
Glaucoma$118,549$72,282$36,631$31,251$155,180$103,533
Corneal Health28,19018,2372,2402,35030,43020,587
Total$146,739$90,519$38,871$33,601$185,610$124,120

Item 1. Financial Statements

FAQ

What is Glaukos's glaucoma — revenue?
Glaukos (GKOS) reported glaucoma — revenue of $155.18M in Q2 2026.
How has Glaukos's glaucoma — revenue changed year-over-year?
Glaukos's glaucoma — revenue increased by 49.9% year-over-year, from $103.53M to $155.18M.
What is the long-term trend for Glaukos's glaucoma — revenue?
Over 4 years (2021 to 2025), Glaukos's glaucoma — revenue has grown at a 16.1% compound annual growth rate (CAGR), from $231.98M to $421.07M.
What does glaucoma — revenue mean?
This metric represents the total net sales generated from the Glaucoma product franchise, specifically excluding any assessed taxes collected from customers. It measures the core commercial performance of the company's micro-invasive glaucoma surgery (MIGS) portfolio and related ophthalmic devices. This figure reflects the market adoption and pricing power of the company's primary therapeutic solutions within the ophthalmic medical technology sector.

Ask your AI about Glaukos's glaucoma — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude